NDC Package 51754-0203-2 Verapamil Hydrochloride

Injection Intravenous - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
51754-0203-2
Package Description:
5 VIAL in 1 CARTON / 2 mL in 1 VIAL
Product Code:
Proprietary Name:
Verapamil Hydrochloride
Non-Proprietary Name:
Verapamil Hydrochloride
Substance Name:
Verapamil Hydrochloride
Usage Information:
Verapamil is indicated for the treatment of supraventricular tachyarrhythmias, including:Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to Verapamil administration.Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation, except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes).In controlled studies in the U.S., about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous Verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in heart rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after Verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. The effect of a single injection lasts for 30–60 minutes when conversion to sinus rhythm does not occur.Because a small fraction (<1.0%) of patients treated with Verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation with an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole—see Contraindications and Warnings), the initial use of intravenous Verapamil hydrochloride should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions). As familiarity with the patient’s response is gained, an office setting may be acceptable.Cardioversion has been used safely and effectively after intravenous Verapamil.
11-Digit NDC Billing Format:
51754020302
Billing Unit:
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
NDC to RxNorm Crosswalk:
  • RxCUI: 1665057 - verapamil HCl 5 MG in 2 ML Injection
  • RxCUI: 1665057 - 2 ML verapamil hydrochloride 2.5 MG/ML Injection
  • RxCUI: 1665057 - verapamil HCl 5 MG per 2 ML Injection
  • RxCUI: 1665061 - verapamil HCl 10 MG in 4 ML Injection
  • RxCUI: 1665061 - 4 ML verapamil hydrochloride 2.5 MG/ML Injection
  • Product Type:
    Human Prescription Drug
    Labeler Name:
    Exela Pharma Sciences, Llc
    Dosage Form:
    Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
    Administration Route(s):
  • Intravenous - Administration within or into a vein or veins.
  • Active Ingredient(s):
    Sample Package:
    No
    FDA Application Number:
    NDA018925
    Marketing Category:
    NDA - A product marketed under an approved New Drug Application.
    Start Marketing Date:
    04-22-2016
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Other Product Packages

    The following packages are also available for this product:

    NDC Package CodePackage Description
    51754-0203-425 VIAL in 1 CARTON / 2 mL in 1 VIAL

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 51754-0203-2?

    The NDC Packaged Code 51754-0203-2 is assigned to a package of 5 vial in 1 carton / 2 ml in 1 vial of Verapamil Hydrochloride, a human prescription drug labeled by Exela Pharma Sciences, Llc. The product's dosage form is injection and is administered via intravenous form.

    Is NDC 51754-0203 included in the NDC Directory?

    Yes, Verapamil Hydrochloride with product code 51754-0203 is active and included in the NDC Directory. The product was first marketed by Exela Pharma Sciences, Llc on April 22, 2016 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 51754-0203-2?

    The contents of this package are billed per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.

    What is the 11-digit format for NDC 51754-0203-2?

    The 11-digit format is 51754020302. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-4-1 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-4-151754-0203-25-4-251754-0203-02